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1 
REGENTS OF UNIV. OF CALIFORNIA V. BROAD INST., INC., 






Appellants consisting of The University of California, the 
University of Vienna, and Emmanuelle Charpentier, ( collectively 
“UC”), appealed a decision of the Patent Trial and Appeal Board 
who unanimously held there was no interference-in-fact between 
UC’s application for CRISPR patents, and the CRISPR patents 
originally awarded to appellees Broad Institute, Inc., Massachusetts 
Institute of Technology, and the President and Fellows of Harvard 
College, (collectively “Broad”).1 The patents disputed involved 
CRISPR-Cas9 technology that enables swift cutting of DNA 
molecules.2 The CRISPR-Cas9 system has two molecules that 
implement a mutation into the DNA, including an enzyme named 
Cas9 that cuts twos stands of DNA at a particular location within 
the genome, allowing DNA bits to be added or removed.3 The other 
molecule is a piece of RNA known as guide RNA (gRNA), which 
helps guide the Cas9 enzyme in cutting the right point within the 
genome.4 The patents that Broad was awarded were confined to the 
use of eukaryotic cells, which is vital in that CRISPR-Cas9 systems 
have not been found to naturally exist in eukaryotes5, such as plant 
 
* Ali Albazzaz is a 2021 DePaul University College of Law J.D. Candidate. Ali 
graduated from the University of Illinois at Chicago (UIC) in 2017, where he 
majored in Biological Sciences. At UIC, Ali enjoyed learning the wonders of the 
scientific realm and its underlying complexities. Ali decided to attend law school 
in order to intertwine his passion for science and law, as he plans to pursue a 
career in the innovative world of patent law.  
1 Regents of Univ. of California v. Broad Inst., Inc., 903 F.3d 1286, 1289 (Fed. 
Cir. 2018). 
2 Id. 
3 What is CRISPR-Cas9?, YOUR GENOME (Dec. 19, 2016), 
https://www.yourgenome.org/facts/what-is-crispr-cas9.  
4 Id.  
5 Eukaryotic Cell, BIOLOGY DICTIONARY, 
https://biologydictionary.net/eukaryotic-cell/ (last visited Oct. 27, 2019).  
Eukaryotic cells have a nucleus and organelles, and are enclosed by a plasma 
membrane. Organisms that consist of eukaryotic cells include protozoa, fungi, 
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and animal cells.6 In contrast, UC’s original publication involved 
CRISPR-Cas9 systems within the prokaryotic cell setting (single 
cell organisms lacking distinct nuclei).7 As genetic editing in the 
form of CRISPR-Cas9 technology enters the realm of eukaryotic 
alteration, the instant case demonstrates how patent jurisprudence 
can serve as an effective catalyst for the progression toward 




A. Factual Background 
 
In August 2012, researchers from UC published an article in 
reference to usage of CRISPR-Cas9 and its ability to be used in vitro 
in a non-cellular experimental environment.8 The UC publication 
did not report any results of experimentation utilizing CRISPR-
Cas9 within a eukaryotic cell.9 In February 2013, researchers from 
the Broad Institute published an article on their triumphant use of 
CRISPR-Cas9 in a human cell line.10 UC and Broad then both 
pursued patent protection for their scientific findings.11  
 
B. Procedural Posture 
 
The Patent and Trial Appeal Board instituted an interference 
(an administrative proceeding to determine priority of invention and 
patentability of invention); however, Broad moved to terminate 
such interference, as they alleged that their successful findings of 
CRISPR-Cas9 usage in eukaryotic cells was patentably distinct 
from UC’s patent claim of CRISPR-Cas9 usage in prokaryotic 
cells.12 Broad’s reasoning for such termination, was based on a 
 
plants and animals. Eukaryotic cells are larger and more complex than 
prokaryotic cells, which are found in Archaea and Bacteria, the other two 
domains of life. 
6 Regents of Univ. of California, 903 F.3d at 1289. 
7 Regents of Univ. of California, 903 F.3d at 1286. 
8 Regents of Univ. of California, 903 F.3d at 1289 (citing J.A. at 4799–804). 
9 Id. 
10 Regents of Univ. of California, 903 F.3d at 1289 (citing J.A. at 4682–86). 
11 Id. 
12 Id. at 1290.  
2
DePaul Journal of Art, Technology & Intellectual Property Law, Vol. 30, Iss. 1 [2020], Art. 4
https://via.library.depaul.edu/jatip/vol30/iss1/4
DEPAUL J. ART, TECH. & IP LAW VOLUME 30 
116             DEPAUL J. ART, TECH. & IP LAW [Vol. XXX: 
 
person of ordinary skill in the art not having a reasonable 
expectation that the CRISPR-Cas9 system would work successfully 
within the confines of a eukaryotic cell.13 In taking such reasoning 
into account, the Board held no such interference-in-fact, as the 
realm of eukaryotic and prokaryotic systems served as non-similar 
entities to one another.14 Therefore, a person of ordinary skill in the 
art would not have had a reasonable expectation of success in 
applying the CRISPR-Cas9 system in eukaryotic cells.15  
 As such, the Board determined that UC’s claims regarding 
CRISPR-Cas9 usage did not render obvious Broad’s claims to its 
successful use in eukaryotic cells.16 Because the respective patents 
were filed in the era of the Pre-America Invents Act (Pre-AIA), the 
US Court of Appeals for the Federal Circuit had jurisdiction to 
resolve the interference issue between the respective parties under 
28 U.S.C. § 1295 (a)(4)(a).17  
Ultimately, the Federal Circuit Judge favored Broad in 
determining there was a lack of reasonable expectation of success 
regarding CRISPR-Cas9’s application into the realm of eukaryotic 
cells.18 Thus, finding no interference-in fact, the Court rendered 
Broad’s usage of CRISPR-Cas9 in eukaryotic cells patentably 
distinct from UC’s usage of CRISPR-Cas9 in prokaryotic cells.19  
 
III. LEGAL ANALYSIS 
 
Before analyzing the issues in the case, the Court mentioned 
that the Board utilized a two-way test to determine whether a claim 
is patentably distinct.20 The Board specifically inquired whether 
“the subject matter of a claim of one party would, if prior art, ha[d] 
anticipated or rendered obvious the subject matter of a claim of the 
opposing party and vice versa.”21 The Court mentioned that if the 
threshold of the two-way test is not adhered to, then no such 
 
13 Regents of Univ. of California, 903 F.3d at 1290. 
14 Id. 
15 Id. 
16 Regents of Univ. of California, 903 F.3d at 1290 (citing J.A. at 49). 
17 Id.  
18 Id. at 1296.  
19 Id. at 1286. 
20 Id. at 1291. 
21 Regents of Univ. of California, 903 F.3d at 1291. 
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interference-in-fact is present.22 When the interference-in-fact 
centers on an obviousness inquiry, the standard of review involves 
a question of law.23  
The Court’s analysis included precedence from Graham v. 
John Deere Co., where the Supreme Court laid factors to frame a 
proper analysis of obviousness including: (1) the scope and content 
of the prior art; (2) the differences between the claims and the prior 
art; (3) the level of ordinary skill in the art; and (4) objective 
considerations of non-obviousness.24  As such, the obviousness 
determination mandates a finding that a person of ordinary skill 
within the art, would have been inspired to combine the teachings 
in prior art, along with having a reasonable expectation of success 
in combining such teachings.25 An analysis of a reasonable 
expectation of success is a question of fact.26 Thus, the Court 
analyzed the issue of obviousness de novo, and the factual findings, 
including the reasonable expectation of success, under a substantial 
evidence standard.27  
Thus, with the standards of review in-place, the Court is to 
analyze the issues of whether the Board: (1) incorrectly included a 
rigid test of obviousness that mandated the prior art to include 
specific instructions, and (2) whether the Board erred in dismissing 







23 Regents of Univ. of California, 903 F.3d at 1291 (citing WBIP, LLC v. Kohler 
Co., 829 F.3d 1317, 1326 (Fed. Cir. 2016)). 
24 Regents of Univ. of California., 903 F.3d at 1291 (citing Graham v. John 
Deere Co., 383 U.S. 1, 17–18, 86 S. Ct. 684, 15 L.Ed.2d 545 (1966); Arctic Cat 
Inc. v. Bombardier Recreational Prods. Inc., 876 F.3d 1350, 1358 (Fed. Cir. 
2017)). 
25 Regents of Univ. of California, 903 F.3d at 1291 (citing In re Stepan Co., 
868 F.3d 1342, 1345–46 (Fed. Cir. 2017)). 
26 Regents of Univ. of California, 903 F.3d at 1291 (citing In re Stepan Co., 
868 F.3d at 1346). 
27 Regents of Univ. of California, 903 F.3d at 1291 (citing In re Mouttet, 
686 F.3d 1322, 1330–31 (Fed. Cir. 2012)).  
28 Regents of Univ. of California, 903 F.3d at 1291. 
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A. Reasonable Expectation of Success 
 
The Court referred to Broad’s expert testimonial from Dr. 
Paul Simons.29 Dr. Simons mentioned discrepancies between 
prokaryotic and eukaryotic cellular conditions that would make the 
functionality of CRISPR-Cas9 in eukaryotes unpredictable.30 The 
unpredictability of such functionality comprised of intracellular 
temperature, the concentration of various ions, pH, and the presence 
of other molecules that may be present in one type of cell, but not 
the other.31  Dr. Simons testimonial included additional matters that 
would render a skilled artisan to not have a reasonable expectation 
of success regarding CRISPR-Cas9’s application in a eukaryotic 
cell.32 The structural differences between the two cell-lines 
included, eukaryotic cells having ribonucleases that are absent in 
prokaryotic cells.33 Notably, ribonucleases specialize in cutting up 
RNA molecules.34 RNA molecules haves an abundance of 
functions, from “translating genetic information to regulating the 
activity of genes during development, cellular differentiation, and 
changing environments.”35 
To further the differences between the two-cell lines, Dr. 
Simons also mentioned that eukaryotic cells degrade double-
stranded RNA, and prokaryotic cells do not.36 What was concerning 
to Dr. Simon, was that the human genome is bigger than an average 
bacterial genome, like a eukaryote.37 In addition, the frequency of 
similar DNA sequences that are present in the human genome is 
different than what is present within a bacterial genome.38 Overall, 
Dr. Simons determined these differences formulated a conclusion 
that a skilled artisan would not have a reasonable expectation of 
 
29 Id. at 1292. 





35Role of RNA in Biology, RNA THERAPEUTICS INSTITUTE, 
https://www.umassmed.edu/rti/biology/role-of-rna-in-biology/ (last visited Oct. 
27, 2019). 
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success in implementing CRISPR-Cas9 within the confines of a 
eukaryotic cell.39 The Court mentioned that UC’s expert witness Dr. 
Dana Carroll was aware of the same issues that persist when 
attempting to implement the CRISPR-Cas9 system within the 
eukaryotic biological regime.40 Because of the uncertain nature in 
implementation, the Court stated such substantial evidence 
represented the issues that could arise in CRISPR-Cas9’s 
application within a eukaryotic cell.41  
The Court referred to UC inventors’ acknowledgment of doubts 
within CRISPR-Cas9’s successful implementation in eukaryotic 
cells.42 There was evidence that UC acknowledged the significance 
of Broad’s success in implementing CRISPR-Cas9 in eukaryotic 
cells.43 The Court also noted that the Board considered evidence in 
reference to other gene editing systems, which were not helpful in 
analyzing whether there was a reasonable expectation of success of 
applying CRISPR-Cas9 in eukaryotic cells.44 Thus, the Court 
supported the Board’s finding of the unpredictable nature of 
CRISPR-Cas9’s application within eukaryotic cells and thus, a lack 
of reasonable expectation of success.45  
 
B. Specific Instructions 
In determining whether the Board erred in adopting a test 
mandating specific instructions in the prior art to establish 
obviousness, the court found no such error.46 The Court focused on 
specific instructions and its correlation to a reasonable expectation 
of success.47 The Board stated that it “look[ed] to whether or not 
there were instructions in the prior art that would be specifically 
relevant to CRISPR-Cas9,” along with “whether there [were] 








45 Regents of Univ. of California, 903 F.3d at 1294. 
46 Id. 
47 Id. at 1295. 
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systems.”48 The Court discussed the Board’s acknowledgement that 
“[s]pecific instructions that are relevant to the claimed subject 
matter or success in similar methods or products have directed 
findings of a reasonable expectation of success.”49 The Court 
concurred with the Board’s recognition that the combination of only 
generalized instructions along with evidence of failures with similar 
subject matter was indicative of a lack of reasonable expectation of 
success.50 The Court mentioned the Board’s finding that there were 
no specific instructions in the art regarding CRISPR-Cas9, that 
would enable one of ordinary skill in the art a reasonable 
expectation of success.51 The Court agreed with the Board’s finding 
that “the failure demonstrated with other systems would have 
indicated the lack of a reasonable expectation of success.”52 Thus, 
the Court saw no error in the Board’s analysis of the lack of specific 
instructions, to go along with prior failures of adopting prokaryotic 
systems to eukaryotic cells based on general instructions.53 
Indicating, that there was indeed a lack of reasonable expectation of 
success.54  
 
C. Relevance of Simultaneous Invention Evidence 
The Court referred to the Board’s expressive recognition 
that simultaneous inventions are evidence of obviousness when 
“considered in light of all the circumstances.”55 The Court 
recognized that simultaneous inventions can impact an obviousness 
analysis in a few ways.56 First, simultaneous inventions serve as 
evidence of the level of skill within the art.57 Second, simultaneous 
 





53 Regents of Univ. of California, 903 F.3d at 1295. 
54 Id. 
55 Regents of Univ. of California, 903 F.3d at 1295 (citing Lindemann 
Maschinenfabrik GMBH v. Am. Hoist & Derrick Co., 730 F.2d 1452, 1460 
(Fed. Cir. 1984)). 
56 Regents of Univ. of California, 903 F.3d at 1295 (citing Monarch Knitting 
Mach. Corp. v. Sulzer Morat GmbH, 139 F.3d 877, 883 (Fed. Cir. 1998)). 
57 Regents of Univ. of California, 903 F.3d at 1295. 
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inventions are objective evidence that persons of ordinary skill in 
the art understand the issue, along with a solution to that issue.58  
 UC’s evidence of simultaneous invention, where six independent 
research groups succeeded in implementing CRISPR-Cas9 in 
eukaryotic cells within a short period of time after UC’s article 
publication, demonstrated compelling evidence that there was a 
motivation to combine the prior art in this manner.59 However, this 
was not necessarily indicative of an expectation of success prior to 
the completion of the experiments.60 The Court ultimately agreed 
with the Board, in that simultaneous invention did not establish a 
reasonable expectation of success, due to the context of the art at the 
time.61 The context of the art included “characteristics of the science 
or technology, its state of advance, the nature of the known choices, 
the specificity or generality of the prior art, and the predictability of 
results in the area of interest.”62 Thus, the Court supported the 
Board’s finding of evidence of simultaneous invention; regarding 
(1) the state of the art, (2) the statements of the inventors, (3) failures 
involving similar technologies, and (4) the remainder of the record 
evidence as relevant to an obviousness determination, but not 




Thus, with the amalgamation of factors brought forth, the 
Court affirmed the Board’s judgement of no interference-in-fact.64 
The Court found that the Board performed an exhaustive analysis 
consisting of: (1) a variety of statements by experts for both parties 
and the inventors themselves, to go along with previous triumphs 
and disappointments in the field; (2), evidence of simultaneous 
invention; and (3), the degree to which the art provided instructions 
for applying the CRISPR-Cas9 technology in eukaryotic 
 
58 Id. 
59 Regents of Univ. of California, 903 F.3d at 1296. 
60 Id. 
61 Regents of Univ. of California, 903 F.3d at 1296 (citing J.A. 23–25).  
62 Id. 
63 Id. 
64 Id.  
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cells.65  The substantial evidence was indicative that there was not a 
reasonable expectation of success, thus, the Board did not err in its 
finding that there was no interference-in-fact.66  
 
IV. CRISPR INTO THE FUTURE 
Regents serves as an emblem of hope as we embark on a new 
decade. The Court’s holding is symbolic of just how patent 
jurisprudence can catalyze innovation, while invoking limitless 
potential. Regents is a blueprint that scientists can favorably adhere 
to as they analytically frame their next genetic editing 
breakthroughs. Since the Court held Broad’s patent to be distinct,67 
Broad’s revolutionary finding of a particularized genetic editing 
technique within eukaryotic cells, combined with the Court’s 
respect for such a finding, is indicative of the Circuit’s admiration 
of risk taking amid scientific enlightenment. A third party who 
wishes to apply CRISPR-Cas9 in eukaryotic cells will need a license 
from Broad to utilize the ground-breaking technology in human 
cells and eukaryotic cells alike, however, CRISPR-Cas9 is just one 
systematic technology. Importantly, other scientists and third 
parties are now free to explore other genetic editing techniques 
within the eukaryotic regime that could spring human medical 
advancement further, as there is now a foundation that such 
techniques in eukaryotic cells will be recognized in the legal world.   
As a result of Regents, there is now an incentive to increase 
genetic editing technique funds for research and development in the 
eukaryotic realm, which could begin an age of expansive medical 
advancement that borders the line of science fiction. As technology 
inevitably improves in the coming-years, our nation could be a 
foundational pillar of genetic advances that can cure and alleviate 
the most persistent diseases.  Medical conditions that are inherently 
genetic, including cancer and hepatitis B, could be at the mercy of 
not only CRISPR-Cas9, but future genetic editing techniques yet to 
be discovered. Had Regents chosen not to recognize genetic 
techniques as patentable within eukaryotic cells, there could have 
been dire ramifications in human health development. For one, 
 
65 Id. 
66 Id.  
67 Regents of Univ. of California, 903 F.3d at 1296-97.  
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scientists’ motivation to battle the nuances that relay in the complex 
genetic make-up of humans, would be considerably stifled.68 There 
would be no inclination to delve into research to combat human 
genetic deficiencies, as the Federal Circuit wouldn’t recognize such 
techniques as patentably distinct.69 With the Court’s recognition that 
such techniques are patentable, the floodgates of human health 
preservation and augmentation is now a reality, as issues of free 
riding would be neutralized in the face of patent doctrine.  
Regents will undoubtedly be remembered as a case that 
united the world of science and law, in which patent jurisprudence 
mediated a collective understanding of human genius in the realm 
of genetic modification. As 2020 commences, an age of discovery 
and wonderment is on the horizon for medical advancement, thanks 









global-trends (last visited Nov. 18, 2019) “Patents serve a different purpose. 
Inventors often have economic motivations to keep the details of their 
inventions secret. The patenting system provides the legal right for a limited 
time to exclude others from making, using, offering for sale, or selling the 
invention, in exchange for public disclosure of the technical information in the 
granted patent.”  
69 David S. Olson, Patent Protection for Genetic Innovation: Monsanto and 
Myriad, 12 CATO SUPREME COURT REVIEW 283, 299 (2013) 
https://www.cato.org/sites/cato.org/files/serials/files/supreme-court-
review/2013/9/olson.pdf.  
“By allowing cDNA to be patented, the Court ensured that some incentives flow 
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